GALLANT: Inspiring Local Champions, Awakening Global Potential

GALLANT is here to inspire local champions and awaken global potential. The time to step up is now.

Tala PH Strengthens Commitment To Empowered, Gender-Inclusive Workplace

Tala continues to uphold its mission to create an empowered and gender-inclusive workplace.

Wyeth Nutrition Drives Sustainability Practices In Nourishing Healthier Tomorrows

Wyeth Nutrition is dedicated to enhancing sustainability practices that support healthier futures for families.

Residential Condo Development Set To Elevate Bacolod Living In Saludad Township

A new residential condo development in Saludad Township is set to redefine living in Bacolod.

Vaccine Booster Restores Full Protection Vs. Covid-19: Pfizer

Pfizer-BioNTech Covid-19 booster is now under a large-scale trial, aims to give full protection against the disease.

Vaccine Booster Restores Full Protection Vs. Covid-19: Pfizer

24
24

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

Pfizer and BioNTech announced Thursday that a large-scale trial of their coronavirus disease 2019 (Covid-19) vaccine booster showed it restored full protection against the disease.

In Phase 3 randomized, controlled trial, a Pfizer-BioNTech booster dose was administered to more than 10,000 individuals 16 years of age and older, who previously received the Pfizer-BioNTech primary two-dose series.

It showed relative vaccine efficacy of 95.6 percent when compared to those who did not receive a booster.

These are the first efficacy results from any randomized, controlled Covid-19 vaccine booster trial.

“These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease,” said Albert Bourla, Pfizer chairman and chief executive officer.

Last month, the U.S. Food and Drug Administration authorized the booster shots for the Pfizer-BioNTech Covid-19 vaccine, allowing a single booster dose of it to be administered at least 6 months after completion of the primary series to individuals 65 years of age and older, and 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2. (PNA)